Page last updated: 2024-10-16

carnitine and Cirrhosis

carnitine has been researched along with Cirrhosis in 18 studies

Research Excerpts

ExcerptRelevanceReference
"Ezetimibe improved hepatic fibrosis but increased hepatic long-chain fatty acids and HbA1c in patients with NAFLD."9.19The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. ( Arai, K; Honda, M; Kaneko, S; Kato, K; Kita, Y; Misu, H; Mizukoshi, E; Nakamura, M; Ota, T; Sunagozaka, H; Takamura, T; Takeshita, Y; Yamada, K; Yamashita, T; Zen, Y, 2014)
" Here, we extend our findings and provide evidence of epithelial-mesenchymal transition (EMT)-associated renal fibrosis caused by PFOS and the protection by l-carnitine."7.85From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate. ( Chang, CC; Chou, HC; Jin, L; Juan, SH; Lin, CY; Wen, LL, 2017)
" Simultaneous treatment with L-carnitine attenuated the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ."7.80L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014)
"L-carnitine supplementation attenuates cardiac fibrosis by increasing prostacyclin production through arachidonic acid pathway, and may be a promising therapeutic option for HFpEF."7.78L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. ( Aizawa, Y; Kamimura, D; Komuro, I; Mano, T; Miwa, T; Ohtani, T; Omori, Y; Sakata, Y; Soga, T; Takeda, Y; Tamaki, S; Tsukamoto, Y; Yamamoto, K, 2012)
"l-Carnitine (LC) plays an essential role in the β-oxidation of long-chain fatty acids in lipid metabolism."5.39L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Vázquez, MJ; Zambrano, S, 2013)
"Ezetimibe improved hepatic fibrosis but increased hepatic long-chain fatty acids and HbA1c in patients with NAFLD."5.19The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. ( Arai, K; Honda, M; Kaneko, S; Kato, K; Kita, Y; Misu, H; Mizukoshi, E; Nakamura, M; Ota, T; Sunagozaka, H; Takamura, T; Takeshita, Y; Yamada, K; Yamashita, T; Zen, Y, 2014)
" Here, we extend our findings and provide evidence of epithelial-mesenchymal transition (EMT)-associated renal fibrosis caused by PFOS and the protection by l-carnitine."3.85From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate. ( Chang, CC; Chou, HC; Jin, L; Juan, SH; Lin, CY; Wen, LL, 2017)
" The aim of the study was to investigate the role of MMPs and their inhibitors (TIMPs), in the pathogenesis of choline deficiency-induced cardiomyopathy, and the way they are affected by carnitine supplementation."3.83Immunohistochemical determination of the extracellular matrix modulation in a rat model of choline-deprived myocardium: the effects of carnitine. ( Giannopoulou, I; Karkalousos, P; Kriebardis, A; Lazaris, A; Liapi, C; Panayiotides, I; Papavdi, A; Perelas, A; Strilakou, A, 2016)
" Simultaneous treatment with L-carnitine attenuated the renal fibrosis (which correlated with a reduction of plasma TGF-β1 levels) and the pro-oxidative and proinflammatory status reported in L-NAME groups, with a concomitant increase in the expression of PPAR-γ."3.80L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Zambrano, S, 2014)
"L-carnitine supplementation attenuates cardiac fibrosis by increasing prostacyclin production through arachidonic acid pathway, and may be a promising therapeutic option for HFpEF."3.78L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. ( Aizawa, Y; Kamimura, D; Komuro, I; Mano, T; Miwa, T; Ohtani, T; Omori, Y; Sakata, Y; Soga, T; Takeda, Y; Tamaki, S; Tsukamoto, Y; Yamamoto, K, 2012)
"Liver fibrosis was apparent at 20 days and 13 weeks."1.48Maternal L-carnitine supplementation improves glucose and lipid profiles in female offspring of dams exposed to cigarette smoke. ( Al-Odat, I; Chan, YL; Chen, H; McGrath, KC; Oliver, BG; Pollock, CA; Saad, S, 2018)
"The study investigates the effects of choline deficiency on myocardial performance in adult rats and the possible modifications after carnitine administration."1.39Heart dysfunction induced by choline-deficiency in adult rats: the protective role of L-carnitine. ( Douzis, ICh; Karkalousos, PL; Lazaris, AC; Liapi, CA; Mourouzis, IS; Pantos, CI; Perelas, AI; Strilakou, AA; Stylianaki, AT, 2013)
"l-Carnitine (LC) plays an essential role in the β-oxidation of long-chain fatty acids in lipid metabolism."1.39L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. ( Arévalo, M; Blanca, AJ; Mate, A; Miguel-Carrasco, JL; Ruiz-Armenta, MV; Vázquez, CM; Vázquez, MJ; Zambrano, S, 2013)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19901 (5.56)18.7374
1990's0 (0.00)18.2507
2000's2 (11.11)29.6817
2010's11 (61.11)24.3611
2020's4 (22.22)2.80

Authors

AuthorsStudies
Emran, T1
Chowdhury, NI1
Sarker, M1
Bepari, AK1
Hossain, M1
Rahman, GMS1
Reza, HM1
Ottria, A1
Hoekstra, AT1
Zimmermann, M1
van der Kroef, M1
Vazirpanah, N1
Cossu, M1
Chouri, E1
Rossato, M1
Beretta, L1
Tieland, RG1
Wichers, CGK1
Stigter, E1
Gulersonmez, C1
Bonte-Mineur, F1
Berkers, CR1
Radstake, TRDJ1
Marut, W1
Zhao, HY1
Li, HY1
Jin, J1
Jin, JZ1
Zhang, LY1
Xuan, MY1
Jin, XM1
Jiang, YJ1
Zheng, HL1
Jin, YS1
Jin, YJ1
Choi, BS1
Yang, CW1
Piao, SG1
Li, C1
Chen, YC1
Cheng, CY1
Liu, CT1
Sue, YM1
Chen, TH1
Hsu, YH1
Huang, NJ1
Chen, CH1
Chou, HC1
Wen, LL1
Chang, CC1
Lin, CY1
Jin, L1
Juan, SH1
Saad, S1
Al-Odat, I1
Chan, YL1
McGrath, KC1
Pollock, CA1
Oliver, BG1
Chen, H2
Chen, DQ1
Cao, G1
Argyopoulos, CP1
Yu, H1
Su, W1
Chen, L1
Samuels, DC1
Zhuang, S1
Bayliss, GP1
Zhao, S1
Yu, XY1
Vaziri, ND1
Wang, M1
Liu, D1
Mao, JR1
Ma, SX1
Zhao, J1
Zhang, Y1
Shang, YQ1
Kang, H1
Ye, F1
Cheng, XH1
Li, XR1
Zhang, L1
Meng, MX1
Guo, Y1
Zhao, YY1
Strilakou, AA1
Lazaris, AC1
Perelas, AI1
Mourouzis, IS1
Douzis, ICh1
Karkalousos, PL1
Stylianaki, AT1
Pantos, CI1
Liapi, CA1
Takeshita, Y1
Takamura, T1
Honda, M1
Kita, Y1
Zen, Y1
Kato, K1
Misu, H1
Ota, T1
Nakamura, M1
Yamada, K1
Sunagozaka, H1
Arai, K1
Yamashita, T2
Mizukoshi, E1
Kaneko, S1
Zambrano, S2
Blanca, AJ2
Ruiz-Armenta, MV2
Miguel-Carrasco, JL2
Arévalo, M2
Mate, A2
Vázquez, CM2
Nishikawa, H1
Osaki, Y1
Strilakou, A1
Perelas, A1
Lazaris, A1
Papavdi, A1
Karkalousos, P1
Giannopoulou, I1
Kriebardis, A1
Panayiotides, I1
Liapi, C1
Kolwicz, SC1
Olson, DP1
Marney, LC1
Garcia-Menendez, L1
Synovec, RE1
Tian, R1
Omori, Y1
Ohtani, T1
Sakata, Y1
Mano, T1
Takeda, Y1
Tamaki, S1
Tsukamoto, Y1
Kamimura, D1
Aizawa, Y1
Miwa, T1
Komuro, I1
Soga, T1
Yamamoto, K1
Vázquez, MJ1
Kao, HJ1
Cheng, CF1
Chen, YH1
Hung, SI1
Huang, CC1
Millington, D1
Kikuchi, T1
Wu, JY1
Chen, YT1
Shirazi, M1
Noorafshan, A1
Kroup, M1
Tanideh, N1
Kobayashi, A1
Yamazaki, N1
Miura, K1
Shirasawa, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714]Phase 1/Phase 260 participants (Anticipated)Interventional2023-11-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for carnitine and Cirrhosis

ArticleYear
Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis.
    Mediators of inflammation, 2015, Volume: 2015

    Topics: Carcinoma, Hepatocellular; Carnitine; Electric Impedance; Fibrosis; Hand Strength; Hepatitis C, Chro

2015

Trials

1 trial available for carnitine and Cirrhosis

ArticleYear
The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial.
    Diabetologia, 2014, Volume: 57, Issue:5

    Topics: Aged; Anticholesteremic Agents; Area Under Curve; Azetidines; Biopsy; Carnitine; Cholesterol; Ezetim

2014

Other Studies

16 other studies available for carnitine and Cirrhosis

ArticleYear
L-carnitine protects cardiac damage by reducing oxidative stress and inflammatory response via inhibition of tumor necrosis factor-alpha and interleukin-1beta against isoproterenol-induced myocardial infarction.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carnitine; Disease Models, Animal; Fibrosis; Inflam

2021
Fatty Acid and Carnitine Metabolism Are Dysregulated in Systemic Sclerosis Patients.
    Frontiers in immunology, 2020, Volume: 11

    Topics: Adult; Aged; Carnitine; Cohort Studies; Cytokines; Dendritic Cells; Etoposide; Fatty Acids; Female;

2020
L-carnitine treatment attenuates renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.
    The Korean journal of internal medicine, 2021, Volume: 36, Issue:Suppl 1

    Topics: Animals; Carnitine; Fibrosis; Hydrogen Peroxide; Kidney; Phosphatidylinositol 3-Kinases; Rats; Rats,

2021
Combined protective effects of oligo-fucoidan, fucoxanthin, and L-carnitine on the kidneys of chronic kidney disease mice.
    European journal of pharmacology, 2021, Feb-05, Volume: 892

    Topics: Animals; Apoptosis; Biomarkers; Carnitine; Cell Line; Disease Models, Animal; Drug Therapy, Combinat

2021
From the Cover: l-Carnitine via PPARγ- and Sirt1-Dependent Mechanisms Attenuates Epithelial-Mesenchymal Transition and Renal Fibrosis Caused by Perfluorooctanesulfonate.
    Toxicological sciences : an official journal of the Society of Toxicology, 2017, Dec-01, Volume: 160, Issue:2

    Topics: Acetylation; Alkanesulfonic Acids; Animals; Carnitine; Cell Line; Cell Movement; Cytoprotection; Dis

2017
Maternal L-carnitine supplementation improves glucose and lipid profiles in female offspring of dams exposed to cigarette smoke.
    Clinical and experimental pharmacology & physiology, 2018, Volume: 45, Issue:7

    Topics: Animals; Biomarkers; Carnitine; Cigarette Smoking; Dietary Supplements; Female; Fibrosis; Glucose; L

2018
Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.
    Nature communications, 2019, 04-01, Volume: 10, Issue:1

    Topics: Acetylcarnitine; Animals; Canavanine; Carnitine; Case-Control Studies; Disease Models, Animal; Disea

2019
Heart dysfunction induced by choline-deficiency in adult rats: the protective role of L-carnitine.
    European journal of pharmacology, 2013, Jun-05, Volume: 709, Issue:1-3

    Topics: Animals; Cardiotonic Agents; Carnitine; Choline Deficiency; Dietary Supplements; Edema, Cardiac; Fib

2013
L-carnitine attenuates the development of kidney fibrosis in hypertensive rats by upregulating PPAR-γ.
    American journal of hypertension, 2014, Volume: 27, Issue:3

    Topics: Animals; Carnitine; Cells, Cultured; Collagen; Connective Tissue Growth Factor; Cytoprotection; Dise

2014
Immunohistochemical determination of the extracellular matrix modulation in a rat model of choline-deprived myocardium: the effects of carnitine.
    Fundamental & clinical pharmacology, 2016, Volume: 30, Issue:1

    Topics: Administration, Oral; Animals; Cardiomyopathies; Carnitine; Choline Deficiency; Disease Models, Anim

2016
Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy.
    Circulation research, 2012, Aug-31, Volume: 111, Issue:6

    Topics: Acetyl-CoA Carboxylase; Animals; Aorta; Blotting, Western; Cardiomegaly; Carnitine; Constriction, Pa

2012
L-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease.
    Journal of hypertension, 2012, Volume: 30, Issue:9

    Topics: Aged; Animals; Carnitine; Delta-5 Fatty Acid Desaturase; Electrophoresis, Capillary; Epoprostenol; F

2012
L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression.
    Biochemical pharmacology, 2013, Apr-01, Volume: 85, Issue:7

    Topics: Animals; Antihypertensive Agents; Carnitine; Collagen Type I; Collagen Type II; Connective Tissue Gr

2013
ENU mutagenesis identifies mice with cardiac fibrosis and hepatic steatosis caused by a mutation in the mitochondrial trifunctional protein beta-subunit.
    Human molecular genetics, 2006, Dec-15, Volume: 15, Issue:24

    Topics: Adipose Tissue; Animals; Base Sequence; Blotting, Western; Carnitine; Chromosome Mapping; Ethylnitro

2006
Comparison of the effects of captopril, tamoxifen and L-carnitine on renal structure and fibrosis after total unilateral ureteral obstruction in the rat.
    Scandinavian journal of urology and nephrology, 2007, Volume: 41, Issue:2

    Topics: Animals; Captopril; Carnitine; Female; Fibrosis; Kidney; Rats; Rats, Sprague-Dawley; Tamoxifen; Uret

2007
Effects of L-carnitine and verapamil on myocardial carnitine concentration and histopathology of Syrian hamster BIO 14.6.
    Cardiovascular research, 1986, Volume: 20, Issue:8

    Topics: Animals; Calcinosis; Cardiomyopathies; Carnitine; Cricetinae; Fibrosis; Mesocricetus; Myocardium; Ne

1986